Was geht hier? IGC WEBSITE UNDER REVISION

IGC KABOOOOOOOOOM run starts https://old.nasdaq.com/symbol/igc/real-time  

IGC great DD buy https://investorshub.advfn.com/boards/...sg.aspx?message_id=158754047  

By now, the potential for cannabinoids like tetrahydrocannabinol (THC) and cannabidiol (CBD) to reduce the symptoms and even help prevent the onset of diseases such as Alzheimer’s has been fairly well-documented by a wide variety of studies (nnw.fm/RRjS8). The global potential for cannabis-based therapies has triggered a medical marijuana arms race, as countries like Canada, Israel and many of those in Western Europe seize the initiative and more boldly go where the U.S. federal government has feared to allow private industry to tread. Rising stars in the sector, such as phytocannabinoid combination therapy developer India Globalization Capital, Inc. (NYSE MKT: IGC) (IGC Profile), are acutely aware of this immense global potential and have begun to position themselves to secure what will no doubt be hotly-contested market share. Investors interested in medicinal marijuana and/or Alzheimer’s treatments will find themselves looking at a global landscape of key players that includes Medical Marijuana, Inc. (OTC: MJNA), the first U.S. publicly traded cannabis company, as well as Canadian pharmaceutical-grade marijuana producers Aphria, Inc. (OTCQB: APHQF) (TSX: APH), MYM Nutraceuticals, Inc. (OTCQB: MYMMF) (CNSX: MYM) and Supreme Pharmaceuticals, Inc. (OTC: SPRWF) (TSXV: FIRE).

As attitudes grow increasingly favorable to the medicinal capabilities of cannabis, the companies that excel in this new field are those focused on the development of therapies that address global market concerns, such as Alzheimer’s. According to the Alzheimer’s Association, Alzheimer’s disease and other dementias will cost the U.S. roughly $259 billion in 2017 and, by 2050, could rise to as much as $1.1 trillion (http://nnw.fm/OzoX8).

Help may be on the way, though, as India Globalization Capital, Inc. (IGC) is now on the verge of bringing a potential blockbuster treatment for Alzheimer’s to market as soon as early 2018 (http://nnw.fm/8pkAv). Through a license agreement with the University of South Florida (http://nnw.fm/Ny7N0), IGC is the exclusive licensee of the U.S. patent filing “THC as a Potential Therapeutic Agent for Alzheimer’s Disease,” putting the company on track with a unique advantage in the global Alzheimer’s drug market, which is currently valued at roughly $3.6 billion (http://nnw.fm/b6AVl).

Novel in vitro data (http://nnw.fm/wvwX7) aggregated by IGC using genetically engineered cell lines add substantial weight to the existing argument about low doses of THC addressing the link between amyloid beta peptide (Aß plaque) buildup in the cerebral cortex/hippocampus and Alzheimer’s (http://nnw.fm/lnxQ1). Given that the dominant therapies for Alzheimer’s cannot stop or reverse disease progression, the mounting evidence that THC and CBD can stop or even reverse the symptoms of this disease (while providing neuroprotective benefits) is huge (http://nnw.fm/f8RVr).

Today’s dominant Alzheimer’s therapies, such as Allergan’s (AGN) Namenda, Daiichi Sankyo’s (DSNKY, DSKYF) Memary, Novartis’s (NVS) Exelon and the drug Aricept developed by Pfizer (PFE) and Eisai (ESALY, ESALF), may soon find themselves supplanted by disruptive new technologies based on extremely old natural substances, like cannabis, which have been in continuous human use for centuries.

Notably, while IGC’s potential is of impressive significance, the company’s market valuation of $10 million is a drop in a bucket compared to other Alzheimer’s players such as Allergan (NYSE: AGN), valued at $60+ billion; Novartis (NYSE: NVS) at $213 billion, and Pfizer (NYSE: PFE) with a market cap of over $210 billion. While IGC has considerable room to grow as investors become aware of its true value, the company offers potentially the most substantial product in the industry. If its aforementioned patent is approved, IGC will own the key therapeutic pathway by which THC interacts with the human body.

The new in vitro data from IGC extend earlier findings regarding the company’s IGC-AD1 product (Hyalolex, http://nnw.fm/Xb0f4), which showed up to 50 percent reduction in the production of the two key peptides that make up the amyloid plaques found in abundance within the brains of Alzheimer’s patients (http://nnw.fm/o5PGh). Moreover, because Alzheimer’s starts several decades before symptoms begin to exhibit, a drug like IGC-AD1, which has demonstrated an ability to decrease production/aggregation of Aß plaque without neurotoxic effects or inebriation, could become a leading prophylactic treatment taken by millions as a way to prevent Alzheimer’s.

Building on this potential, IGC is gearing up to commercialize a non-inebriating liquid supplement version of the product for the licensed medical dispensary market (http://nnw.fm/4RgWz), which has demonstrated an ability to enhance mitochondrial function (a trigger for Alzheimer’s pathophysiology) by as much as 60 percent in vitro (http://nnw.fm/0kf0N). This readily commercialized combination therapy could give IGC significant, immediate ground game in this burgeoning retail space and help support the company’s clinical work. This one-two punch approach, with a food supplement in one hand and an FDA prophylactic/therapeutic indication in the other, is as powerful as it is solidly backed by exclusively-licensed IP.

Germany alone has nearly 83 million people, and the most common cause behind the 1.6 million-plus dementia cases in that country is Alzheimer’s (http://nnw.fm/Y1F5z). As such, the recent announcement that IGC has entered into an MOU with leading Hamburg-based medical cannabis information and services provider MediCann Handels GmbH (http://nnw.fm/ssMn9) to import and distribute IGC’s cannabinoid-based therapies to German pharmacies has been music to savvy investors’ ears. This is a serious boon for IGC, which marks the first step of many along the company’s path to commercialization and is a real sweetheart of a deal, with MediCann footing the bill for the logistics, as well as sales and marketing  

sen https://old.nasdaq.com/symbol/igc/after-hours  

seit Tagen /  https://old.nasdaq.com/symbol/igc/after-hours  

Im Tagesverlauf immer runter und günstig umziehen sammeln und danach nachbörslich öfters hoch , habe ich jetzt öfter schon beobachtet
https://old.nasdaq.com/symbol/igc/after-hours





wow see IGC KABOOOOOOOOOOOM $1,42

IGC LOOKS NOW FANTASTIC - GREAT STOCK NOW -GREAT UPTRENDCHART NOW - STRONG BUY

https://stockcharts.com/h-sc/ui?s=IGC

https://www.ariva.de/india_globalization_capital-aktie/chart

Has great MJ products

Has a dream uptrend chart for days and weeks

Has a lot of imagination

Has a super structure More and more buyers want to be and the stock is making its way,

we will see new ones high.


AGAIN CLOSED ON HIGH - STROOOOOONG BUY NOW

SOOOON $2 - $3 - $5 .....


all only imho
 

https://www.otcmarkets.com/stock/BIGC/news
 

https://stocktwits.com/symbol/IGC  

Dein gepushe reicht jetzt langsam, alles gut?  

https://old.nasdaq.com/symbol/igc/stock-chart  

Jetzt 1,80$.
Nicht zu lange halten, da sehr volatil.  

kommt wieder Musi rein  

..... darum ist der Marihuana Sektor heiß und fast alle mal so alle Aktien gehen nach oben  

Mich wundern die zwei Sparten, die ich hier finde. Zum einen die Leasing-Sparte für Großmaschinen und auf der anderen Seite die Canabinoid-Forschung. Das ist thematisch ja so weit voneinander entfernt wie es nur sein kann. Kann mir das jemand erklären?
Der aktuelle Anstieg ist wahrscheinlich eher dem Canabis-Sektor zuzuordnen, oder wie seht ihr das?

Ich habe mir mal eine kleine Posi gegönnt, der Chart sieht sehr gut aus.

Mhm, der zweite Wert den ich eher als kurzfrist Invest sehe... Da werde ich meiner Langzeit-Anlagestrategie in letzter Zeit zum zweiten Mal untreu...  

ist ein Fake Unternehmen mit keinerlei nennenswerter Operation. Das Geschäftsmodell ist Pump and Dump. Das funktioniert seit 20 Jahren. Der CEO springt auf aktuelle Themen und macht Werbung dafür und pumpt die Aktie mit seinen Freunden hoch, um neue Aktien zu issuen oder selber zu verkaufen. Mich wundert es, dass er auf den COCID 19 Vaccine Hype nicht aufgesprungen ist. Absolut substanzlos.
Nichtdestoweniger kann man damit von Zeit zu Zeit Geld verdienen, wenn es genug gefallen ist. Sonst ist das Risiko zu hoch. Der letzte Pump lieferte hier eine 40x Fachung vom 0.4 aus.
Wenn das Ding auf 0.3 fallen sollte, kann man zugreifen. Der CEO möchte weiterhin seine Spielchen treiben, dafür muss das Ding in Nasdaq gelistet sein, und dafür ist ein Aktienkurs von mindestens $1 nötig. Ab 1 kann man dann sein Geld wieder rausziehen und den Rest laufen lassen.
Das Risiko besteht, dass der CEO aufhört und damit das Unternehmen bk erklärt. Irgendwann.
Daher ist erhebliche Vorsicht geboten. Dietmar Scherf, der in Deutschland ein paar Pennyaktien promotet, ist wahrscheinlich auch unter verschiedenen aliases hier in den Foren unterwegs und macht hier und da Werbung. Die letzte Aktie, die er promotet hatte, ging bk und viele haben Geld dort verloren. Trotz Warnungen unserer Seite.
Ansonsten, viel Glück!